Hubbry Logo
ChikungunyaChikungunyaMain
Open search
Chikungunya
Community hub
Chikungunya
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Chikungunya
Chikungunya
Chikungunya
View on Wikipedia
from Wikipedia

Chikungunya
Rash from chikungunya
Pronunciation
SpecialtyInfectious disease
SymptomsFever, joint pain, headache, muscle pain, joint swelling, and rash.[2]
ComplicationsLong term joint pain[2]
Usual onset2 to 14 days after exposure[3]
DurationUsually less than a week[2]
CausesChikungunya virus spread by mosquitoes[3]
Diagnostic methodBlood test for viral RNA or antibodies[3]
Differential diagnosisDengue fever, Zika fever[3]
PreventionChikungunya vaccine, Mosquito control, avoidance of bites[4]
TreatmentSupportive care[3]
PrognosisRisk of death ~ 1 in 1,000[4]
Frequency> 1 million (2014)[3]

Chikungunya is an infection caused by the chikungunya virus.[3] The most common symptoms are fever and joint pain,[2] typically occurring four to eight days after the bite of an infected mosquito;[3] however some people may be infected without showing any symptoms.[5] Other symptoms may include headache, muscle pain, joint swelling, and a rash.[2] Symptoms usually improve within a week; however, occasionally the joint pain may last for months or years.[2][6] The very young, old, and those with other health problems are at risk of more severe disease.[2]

The virus is spread between people by two species of mosquito in the Aedes genus: Aedes albopictus and Aedes aegypti,[3] which mainly bite during the day,[7][8] particularly around dawn and in the late afternoon.[9] The virus may circulate within a number of animals, including birds and rodents.[3] Diagnosis is done by testing the blood for either viral RNA or antibodies to the virus.[3] The symptoms can be mistaken for those of dengue fever and Zika fever, which are spread by the same mosquitoes.[3] It is believed most people become immune after a single infection.[2]

The best means of prevention are overall mosquito control and the avoidance of bites in areas where the disease is common.[4] This may be partly achieved by decreasing mosquitoes' access to water, as well as the use of insect repellent and mosquito nets. Chikungunya vaccines have been approved for use in the United States[10] and in the European Union.[11][12][13] No specific treatment for chikungunya is available; supportive care is recommended, with symptomatic treatment of fever and joint swelling.[4]

The chikungunya virus is widespread in tropical and subtropical regions where warm climates and abundant populations of its mosquito vectors (A. aegypti and A. albopictus) facilitate its transmission.[3] The disease was first identified in 1952 in Tanzania and named based on the Makonde words for "to become contorted".[3] While the disease is endemic in Africa and Asia, outbreaks have been reported in Europe and the Americas since the 2000s.[3] In 2014, more than a million suspected cases occurred globally.[3] Chikungunya has become a global health concern due to its rapid geographic expansion, recurrent outbreaks, the lack of effective antiviral treatments, and potential to cause severe symptoms and death.[14]

Signs and symptoms

[edit]

Chikungunya can be asymptomatic, with estimates of between 17% and 40% of infections showing no symptoms.[5] For those experiencing symptoms, they typically begin with a sudden high fever above 39 °C (102 °F) around 3 to 7 days after the bite of an infected mosquito.[15][5] The fever is often accompanied by severe muscle and joint pain, which affects multiple joints in the arms and legs and is often symmetric – i.e. if one elbow is affected, the other is as well.[16][5] People with chikungunya also frequently experience headaches, back pain, nausea, and fatigue.[16] Around half of those affected develop a rash, with reddening and sometimes small bumps on the palms, foot soles, torso, and face.[16]

For some, the rash remains constrained to a small part of the body; for others, the rash can be extensive, covering more than 90% of the skin.[15] Some people experience gastrointestinal issues, with abdominal pain and vomiting. Others experience eye problems, namely sensitivity to light, conjunctivitis, and pain behind the eye.[16] This first set of symptoms – called the "acute phase" of chikungunya – lasts around a week, after which most symptoms resolve on their own.[16]

For those with severe symptoms, approximately 30% to 40% continue to have symptoms after the "acute phase" resolves.[5][16] The lasting symptoms tend to be joint pains: arthritis, tenosynovitis, and/or bursitis.[16] If the affected person has pre-existing joint issues, these tend to worsen.[16] Overuse of a joint can result in painful swelling, stiffness, nerve damage, and neuropathic pain.[16] Typically the joint pain improves with time; however, the chronic stage can last anywhere from a few months to several years.[16]

Almost all symptomatic cases feature joint pain, generally in more than one joint.[17] Pain most commonly occurs in peripheral joints, such as the wrists, ankles, and joints of the hands and feet as well as some of the larger joints, typically the shoulders, elbows and knees.[17][18] Joints are more likely to be affected if they have previously been damaged by disorders such as arthritis.[18] Pain may also occur in the muscles or ligaments. In more than half of cases, normal activity is limited by significant fatigue and pain.[17] Infrequently, inflammation of the eyes may occur in the form of iridocyclitis, or uveitis, and retinal lesions may occur.[19] Temporary damage to the liver may occur.[20]

People with chikungunya occasionally develop long term neurologic disorders, most frequently swelling or degeneration of the brain, inflammation or degeneration of the myelin sheaths around neurons, Guillain–Barré syndrome, acute disseminated encephalomyelitis, hypotonia (in newborns), and issues with visual processing.[16]

Newborns, the elderly, and those with diabetes, heart disease, liver and kidney diseases, and human immunodeficiency virus infection tend to have more severe cases of chikungunya. Fewer than 1 in 1,000 people with symptomatic chikungunya die of the disease; generally these are people with pre-existing health conditions.[16][5]

Transmission

[edit]

Chikungunya is generally transmitted from mosquitoes to humans. Chikungunya is spread through bites from Aedes mosquitoes, specifically A. aegypti (Egyptian mosquito) and A. albopictus (Tiger mosquito).[3] Because high amounts of virus are present in the blood during the first few days of infection, the virus can spread from an infected human to a mosquito, where it replicates without harming the mosquito. Subsequently, a bite from the infected mosquito will transmit the virus back to a human.[3] The incubation period ranges from one to twelve days and is most typically three to seven.[17]

Rarely, the disease can be transmitted from mother to child during pregnancy or at birth, in women who become infected a few days before delivery.[5]

Mechanism

[edit]

Chikungunya virus is passed to humans when a bite from an infected mosquito breaks the skin and introduces the virus into the body. The virus initially replicates in cells near the location of the bite; from here it enters the lymphatic system and the bloodstream, enabling it to circulate to organs and tissues which become infected. Most frequently it reproduces in the lymphatic system and the spleen, as well as peripheral joints, muscles and tendons where symptoms frequently occur; it appears that the virus is able to penetrate and replicate in many different types of cells. [21] In severe cases it can infect the brain and liver.[22][21]

During the acute phase of infection, large numbers of infectious virus particles are present in the bloodstream, making it very likely that an uninfected mosquito will pick up the virus if it bites the human host.[22] [21]

During the first few days of infection, the host's innate immune system is activated, producing type I interferons and inflammatory cytokines to fight the infection. This generates the fever and localised inflammation which is characteristic of the disease.[21][23] It takes about a week before the host's adaptive immune system begins to develop antibodies which eventually clear the virus from the bloodstream.[24] However the virus can persist within specific tissues, especially the joints, causing long term inflammation and pain in chronic cases.[23]

The virus has mechanisms which help it to evade the immune response. Within an infected cell, the viral nonstructural protein 2 (nsP2) interferes with the JAK-STAT signalling pathway to hinder it from triggering an antiviral response.[25] The virus can induce apoptosis (programmed cell death) in host cells; virus laden debris from apoptosis is engulfed by macrophages which in turn become infected.[26] The virus also seems to be able to evade T lymphocytes which seek to target and destroy the virus particles.[27]

Diagnosis

[edit]

Chikungunya is diagnosed on the basis of clinical, epidemiological, and laboratory criteria. Clinically, acute onset of high fever and severe joint pain would lead to suspicion of chikungunya. Epidemiological criteria consist of whether the individual has traveled to or spent time in an area in which chikungunya is present within the last twelve days (i.e., the potential incubation period). Laboratory criteria include a decreased lymphocyte count consistent with viremia. However a definitive laboratory diagnosis can be accomplished through viral isolation, RT-PCR, or serological diagnosis.[28]

The differential diagnosis may include other mosquito-borne diseases, such as dengue or malaria, or other infections such as influenza. Chronic recurrent polyarthralgia occurs in at least 20% of chikungunya patients one year after infection, whereas such symptoms are uncommon in dengue.[29]

Virus isolation provides the most definitive diagnosis, but takes one to two weeks for completion and must be carried out in biosafety level III laboratories.[30] The technique involves exposing specific cell lines to samples from whole blood and identifying chikungunya virus-specific responses. RT-PCR using nested primer pairs is used to amplify several chikungunya-specific genes from whole blood, generating thousands to millions of copies of the genes to identify them. RT-PCR can also quantify the viral load in the blood. Using RT-PCR, diagnostic results can be available in one to two days.[30] For rapid identification and genotyping of the chikungunya virus, a method combining RT-PCR with restriction fragment length polymorphism (RFLP) analysis can be used. It is based on amplifying a specific 648 bp fragment of the nsP2 gene, encoding nonstructural protein 2. The unique pattern of restriction sites for the endonucleases PspEI, PvuII, and DraI within this fragment allows for the discrimination of the four major virus genotypes.[31]

Serological diagnosis requires a larger amount of blood than the other methods and uses an ELISA assay to measure chikungunya-specific IgM levels in the blood serum. One advantage offered by serological diagnosis is that serum IgM is detectable from 5 days to months after the onset of symptoms, but drawbacks are that results may require two to three days, and false positives can occur with infection due to other related viruses, such as o'nyong'nyong virus and Semliki Forest virus.[30]

Presently,[when?] there is no specific way to test for chronic signs and symptoms associated with chikungunya fever although nonspecific laboratory findings such as C reactive protein and elevated cytokines can correlate with disease activity.[32]

Prevention

[edit]
A. aegypti mosquito biting a person

Although an approved vaccine exists, the most effective means of prevention are protection against contact with disease-carrying mosquitoes and controlling mosquito populations by limiting their habitat.[4] Access to the chikungunya vaccine remains limited in many endemic regions.[citation needed] Mosquito control focuses on eliminating standing water where mosquitos lay eggs and develop as larvae.[33]

Vaccination

[edit]
This section is an excerpt from Chikungunya vaccine.[edit]

Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus.[34][35]

The most commonly reported side effects include headache, fatigue, muscle pain, joint pain, fever, nausea and tenderness at the injection site.[36]

The first chikungunya vaccine was approved for medical use in the United States in November 2023.[36] Chikungunya vaccines were also authorized in the European Union in May 2024.[37][38][39]

Treatment

[edit]

No specific treatment for chikungunya is available.[4] Supportive care is recommended, and symptomatic treatment of fever and joint swelling includes the use of nonsteroidal anti-inflammatory drugs such as naproxen, non-aspirin analgesics such as paracetamol (acetaminophen) and fluids.[4][5] Aspirin is not recommended due to the increased risk of bleeding. Despite anti-inflammatory effects, corticosteroids are not recommended[5] during the acute phase of disease, as they may cause immunosuppression and worsen infection.[18]

Chronic arthritis

[edit]

In those who have more than two weeks of arthritis, ribavirin may be useful.[4] The effect of chloroquine is not clear.[4] It does not appear to help acute disease, but tentative evidence indicates it might help those with chronic arthritis.[4] Steroids do not appear to be an effective treatment.[4] NSAIDs and simple analgesics can be used to provide partial symptom relief in most cases. Methotrexate, a drug used in the treatment of rheumatoid arthritis, has been shown to have a benefit in treating inflammatory polyarthritis resulting from chikungunya, though the drug mechanism for improving viral arthritis is unclear.[40]

Prognosis

[edit]

The mortality rate of chikungunya is slightly less than 1 in 1000.[41] Those over the age of 65, infants, and those with underlying chronic medical problems are most likely to have severe complications.[42] Newborn infants are especially vulnerable as they lack fully developed immune systems, and may pick up the infection through vertical transmission from their mother.[42] The likelihood of prolonged symptoms or chronic joint pain is increased with increased age and prior rheumatological disease.[43][44]

Epidemiology

[edit]
Main article: Epidemiology of chikungunya
Dark green denotes countries with current or previous local transmission of chikungunya virus, per US Centers for Disease Control and Prevention (CDC) as of September 2019.
A. albopictus distribution as of December 2007
Dark blue: Native range
Teal: introduced

Historically, chikungunya has been present mostly in the developing world. The disease causes an estimated 3 million infections each year.[45] Epidemics in the Indian Ocean, Pacific Islands, and in the Americas, continue to change the distribution of the disease.[46] In Africa, chikungunya is spread by a sylvatic cycle in which the virus largely cycles between other non-human primates, small mammals, and mosquitos between human outbreaks.[47]

During outbreaks, due to the high concentration of virus in the blood of those in the acute phase of infection, the virus can circulate from humans to mosquitoes and back to humans.[47] The transmission of the pathogen between humans and mosquitoes that exist in urban environments was established on multiple occasions from strains occurring on the eastern half of Africa in non-human primate hosts.[33] This emergence and spread beyond Africa may have started as early as the 18th century.[33]

Available data does not indicate whether the introduction of chikungunya into Asia occurred in the 19th century or more recently, but this epidemic Asian strain causes outbreaks in India and continues to circulate in Southeast Asia.[33] In Africa, outbreaks were typically tied to heavy rainfall causing increased mosquito population. In recent outbreaks in urban centers, the virus has spread by circulating between humans and mosquitoes.[18]

Global rates of chikungunya infection are variable, depending on outbreaks. When chikungunya was first identified in 1952, it had a low-level circulation in West Africa, with infection rates linked to rainfall. Beginning in the 1960s, periodic outbreaks were documented in Asia and Africa. Since 2005, following several decades of relative inactivity, chikungunya has re-emerged and caused large outbreaks in Africa, Asia, and the Americas. In India, for instance, chikungunya re-appeared following 32 years of absence of viral activity.[48]

Outbreaks have occurred in Europe, the Caribbean, and South America, areas in which chikungunya was not previously transmitted. Local transmission has also occurred in the United States and Australia, countries in which the virus was previously unknown.[18] In 2005, an outbreak on the island of Réunion was the largest then documented, with an estimated 266,000 cases on an island with a population of approximately 770,000.[49] In a 2006 outbreak, India reported 1.25 million suspected cases.[50]

Chikungunya was introduced to the Americas in 2013, first detected on the French island of Saint Martin,[51] and for the next two years in the Americas, 1,118,763 suspected cases and 24,682 confirmed cases were reported by the PAHO.[52] In 2023, Brazil experienced a significant outbreak, with over 180,000 cases reported, prompting intensified public health interventions and renewed research efforts on viral mutations and transmission patterns[53]

An analysis of the genetic code of chikungunya virus suggests that the increased severity of the 2005–present outbreak may be due to a change in the genetic sequence which altered the E1 segment of the virus' viral coat protein, a variant called E1-A226V. This mutation potentially allows the virus to multiply more easily in mosquito cells.[54] The change allows the virus to use Aedes albopictus as a vector in addition to the more strictly tropical main vector, Aedes aegypti.[55] Enhanced transmission of chikungunya virus by A. albopictus could mean an increased risk for outbreaks in other areas where the mosquito is present.[56] A. albopictus is an invasive species which since the 1960's has spread through Europe, the Americas, the Caribbean, Africa, and the Middle East.[57]

After the detection of zika virus in Brazil in April 2015, the first ever in the Western Hemisphere,[58][59] it is now[when?] thought some chikungunya and dengue cases could in fact be zika virus cases or coinfections.[citation needed]

Since the start of 2025, and as of 25 February, more than 30,000 chikungunya virus cases and 14 related deaths have been reported across 14 countries and territories in the Americas, Africa, Asia, and Europe.[60]

History

[edit]

The disease was first described by Marion Robinson[61] and W.H.R. Lumsden[62] in a pair of 1955 papers, following an outbreak in 1952 on the Makonde Plateau, along the border between Mozambique and Tanganyika (the mainland part of modern-day Tanzania). Since then outbreaks have occurred occasionally in Africa, South Asia, and Southeast Asia; recent outbreaks have spread the disease over a wider range.[citation needed]

The first recorded outbreak may have been in 1779.[63] This is in agreement with the molecular genetics evidence that suggests it evolved around the year 1700.[64]

According to the original paper by Lumsden, the term 'chikungunya' is derived from the Makonde root verb kungunyala, meaning to dry up or become contorted. In concurrent research, Robinson[citation needed] glossed the Makonde term more specifically as "that which bends up". It is understood to refer to the contorted posture of people affected with severe joint pain and arthritic symptoms associated with this disease.[65] Subsequent authors overlooked the references to the Makonde language and assumed the term to have been derived from Swahili, the lingua franca of the region and part of a different branch of Bantu languages. The erroneous attribution to Swahili has been repeated in numerous print sources.[66]

In July 2025, a severe outbreak occurred in China’s Guangdong province. Seven thousand people tested positive for the disease, although symptoms were said to be minor for 95% of those people.[67]

Research

[edit]

Chikungunya is one of more than a dozen agents researched as a potential biological weapon.[68][69]

This disease is part of the group of neglected tropical diseases.[70]

Chikungunya virus

[edit]

Virology

[edit]
Chikungunya virus
The Chikungunya virus structure at atomic resolution has been constructed utilising UCSF Chimera software
Chikungunya virus structure at atomic resolution. Bar = 100 Å[71]
Virus classification Edit this classification
(unranked): Virus
Realm: Riboviria
Kingdom: Orthornavirae
Phylum: Kitrinoviricota
Class: Alsuviricetes
Order: Martellivirales
Family: Togaviridae
Genus: Alphavirus
Species:
Alphavirus chikungunya

Chikungunya virus is a member of the genus Alphavirus, and family Togaviridae. Chikungunya virus features an icosahedral capsid surrounded by a lipid envelope, with a diameter ranging from 60 to 70 nm.[72] It was first isolated in 1953 in Tanzania and is an RNA virus with a positive-sense single-stranded genome of about 11.6kb.[73] It is a member of the Semliki Forest virus complex and is closely related to Ross River virus, O'nyong'nyong virus, and Semliki Forest virus.[74] Because it is transmitted by arthropods, namely mosquitoes, it can also be referred to as an arbovirus (arthropod-borne virus). In the United States, it is classified as a category B priority pathogen,[75] and work requires biosafety level III precautions.[76]

Three genotypes of this virus have been described, each with a distinct genotype and antigenic character: West African, East/Central/South African, and Asian genotypes.[77] The Asian lineage originated in 1952 and has subsequently split into two lineages – India (Indian Ocean Lineage) and South East Asian clades. This virus was first reported in the Americas in 2014. Phylogenetic investigations have shown two strains in Brazil – the Asian and East/Central/South African types – and that the Asian strain arrived in the Caribbean (most likely from Oceania) in about March 2013.[78] The rate of molecular evolution was estimated to have a mean rate of 5 × 10−4 substitutions per site per year (95% higher probability density 2.9–7.9 × 10−4).[78]

The chikungunya virus genome consists of structural and non-structural proteins as typical of alphavirus genomic organization.[79] The structural proteins, including the capsid, E3, E2, 6K and E1, are responsible for encapsulating the viral genome and assembling new viral particles. These proteins are critical for viral entry into host cells. Meanwhile, the non-structural proteins, nsP1, nsP2, nsP3, and nsP4, play essential roles in viral replication, translation, and immune evasion.[79]

Viral replication

[edit]
Transmission electron micrograph of chikungunya virus particles

The virus consists of four nonstructural proteins and three structural proteins.[33] The structural proteins are the capsid and two envelope glycoproteins: E1 and E2, which form heterodimeric spikes on the viron surface. E2 binds to cellular receptors in order to enter the host cell through receptor-mediated endocytosis. E1 contains a fusion peptide which, when exposed to the acidity of the endosome in eukaryotic cells, dissociates from E2 and initiates membrane fusion that allows the release of nucleocapsids into the host cytoplasm, promoting infection.[80] The mature virion contains 240 heterodimeric spikes of E2/E1, which after release, bud on the surface of the infected cell, where they are released by exocytosis to infect other cells.[73]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Chikungunya

View on Grokipedia
from Grokipedia

Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), an enveloped, positive-sense single-stranded RNA virus belonging to the alphavirus genus within the Togaviridae family. The virus is primarily transmitted to humans through bites from infected Aedes aegypti and Aedes albopictus mosquitoes, which acquire it from viremic individuals and subsequently spread it during blood meals. The name "chikungunya" originates from a word in the Kimakonde language of southeastern Tanzania, meaning "to become contorted," reflecting the stooped posture sufferers adopt due to incapacitating joint pain. Infection typically manifests 3–7 days after a bite, with most cases featuring sudden high fever, severe often affecting multiple joints symmetrically, , , , and ; can persist for weeks to months or longer, leading to chronic in some individuals, particularly the elderly. While fatalities are rare (mortality rate under 1% in reported outbreaks), complications such as neurological involvement, , or severe can occur, especially in vulnerable populations like neonates and those with comorbidities. There is no specific antiviral treatment; relies on supportive care including analgesics, hydration, and , though nonsteroidal drugs are cautioned due to risks of . First identified during an outbreak in in 1952, CHIKV remained largely confined to and until major epidemics beginning in 2004–2005 on Island and spreading to , , and the , where over 1.7 million suspected cases were reported in the alone from 2013–2017. As of 2025, the virus has been documented in over 115 countries across , , , and the , with ongoing urban transmission driven by competent vector mosquitoes and human mobility; local transmission has occurred in and the , though sustained autochthonous spread remains limited in temperate regions. Prevention centers on —eliminating breeding sites, using insecticides, and personal protection via repellents and clothing—while a single-dose live-attenuated was approved in 2023 for adults at high risk in endemic areas, though it is not yet widely deployed globally.

Etiology and Virology

Viral Characteristics

Chikungunya virus (CHIKV) belongs to the genus Alphavirus within the family Togaviridae, characterized as an enveloped, mosquito-borne RNA virus. The viral genome consists of a single-stranded, positive-sense RNA molecule approximately 11.8 kb in length, encoding two open reading frames that produce non-structural proteins for replication and structural proteins forming the virion. This genomic organization facilitates efficient translation upon host cell entry, resembling eukaryotic mRNA with a 5' cap and 3' poly-A tail. The mature virion measures about 70 nm in diameter, featuring a lipid envelope studded with 240 heterodimers of the glycoproteins E1 and E2, which mediate receptor binding and membrane fusion during entry. E1 is responsible for fusion with endosomal membranes at low pH, while E2 handles attachment to host cells; mutations in these proteins, such as A226V in E1, have been empirically linked to altered vector tropism by enhancing viral replication efficiency in certain mosquito species. Capsid protein C packages the genome, and subgenomic RNA directs synthesis of these structural components post-replication. CHIKV exhibits three primary genetic lineages—East/Central/South African (ECSA), West African (WA), and Asian—distinguished by phylogenetic analyses of complete genomes, with ECSA further diversifying into sublineages like the lineage. These lineages display variations in virulence-associated and adaptive , such as those in E1/E2 influencing replication kinetics and host adaptation, as evidenced by comparative sequencing of outbreak strains. Empirical studies confirm lineage-specific evolutionary pressures, with ECSA strains showing heightened epidemic potential due to accumulated substitutions enhancing fitness without uniform increases in lethality.

Transmission Dynamics

![Aedes aegypti mosquito biting human][float-right] Chikungunya virus (CHIKV) is primarily transmitted through the bites of infected female Aedes aegypti and Aedes albopictus mosquitoes, which serve as the principal vectors in urban and peri-urban settings. A. aegypti predominates in tropical regions, thriving in densely populated areas due to its preference for breeding in artificial water-holding containers such as tires, flower pots, and discarded items, while A. albopictus, an invasive species, facilitates spread into temperate zones through its adaptability to cooler climates and container breeding. Both species exhibit daytime biting behavior, peaking in early morning and late afternoon, aligning with human activity patterns that enhance contact rates. The transmission cycle involves a human-mosquito-human amplification loop, where mosquitoes acquire CHIKV during blood meals from viremic individuals, typically within the first week of illness when viral loads peak at up to 10^9 RNA copies per milliliter. Following ingestion, the virus undergoes an extrinsic incubation period in the mosquito of 2–14 days (commonly 8–12 days), after which it disseminates to salivary glands, enabling infection of new human hosts upon subsequent bites. Human incubation period ranges from 2–12 days (median 4–8 days), during which viremia persists for 5–10 days post-symptom onset, though occasionally extending to 12 days, sustaining the cycle in endemic areas. Sustained human-to-human transmission without vector involvement does not occur. Rare non-vector modes include perinatal , particularly intrapartum when maternal coincides with delivery, and potential sexual transmission evidenced by CHIKV RNA detection in semen up to 30 days post-onset, though confirmed cases remain limited. Environmental factors amplify dynamics: warmer temperatures (optimal 25–30°C) and high humidity accelerate mosquito development and , while proliferates breeding sites, and international introduces strains to naive populations, as seen in outbreaks seeded by imported cases.

Pathophysiology

Infection Mechanism

Chikungunya virus (CHIKV), an with a positive-sense single-stranded , initiates infection by attaching to host cell receptors primarily through its E2 , which interacts with molecules such as Mxra8 on mammalian cells including dermal fibroblasts, hepatocytes, and musculoskeletal cells. This attachment facilitates clathrin-mediated , where the viral particle is internalized into endocytic vesicles. In the acidic environment of the , the E1 undergoes conformational changes, enabling fusion of the with the endosomal membrane and release of the genomic into the . Upon cytoplasmic entry, the viral serves directly as mRNA for by host ribosomes, producing non-structural proteins nsP1 through nsP4, which assemble into replication complexes associated with modified intracellular membranes such as cytopathic vacuoles derived from the . These complexes initiate replication by synthesizing a complementary negative-sense intermediate, which then templates the production of new positive-sense genomic and subgenomic for structural protein expression. Replication occurs exclusively in the , independent of nuclear processes, and relies on host factors including channels for efficient amplification in both and cells. Initial replication at the dermal inoculation site in fibroblasts proceeds asymptomatically, allowing local amplification before via migrating cells or bloodstream to distal tissues. Structural proteins, translated from the subgenomic , include the protein that encapsidates the genomic to form nucleocapsids, while E1 and E2 glycoproteins are processed through the host secretory pathway and trafficked to the plasma membrane. Assembly culminates in nucleocapsid docking to the cytoplasmic tails of E2 at the plasma membrane, driving virion where the acquires a lipid envelope studded with E1/E2 heterodimers. Egress primarily occurs via this plasma membrane mechanism, though host machinery may contribute to intracellular aspects of the cycle. This process enables efficient production of progeny virions capable of further cell-to-cell spread.

Immune Response and Persistence

The innate immune response to Chikungunya virus (CHIKV) infection involves rapid activation of pattern recognition receptors such as RIG-I and , leading to type I (IFN) production and subsequent induction of interferon-stimulated genes (ISGs) that restrict . However, CHIKV evades this pathway through its nonstructural protein 2 (nsP2), which inhibits RIG-I/ signaling, antagonizes JAK-STAT pathways, and suppresses IFN-β promoter activity, thereby dampening the antiviral state in infected cells. This evasion contributes to high during the acute phase, as observed in and mouse models where nsP2-deficient mutants elicit stronger IFN responses and reduced viral loads. Adaptive follows, with IgM antibodies detectable within days of symptom onset, peaking at 1-2 weeks, and playing a neutralizing role in limiting early dissemination, while IgG occurs by 2-4 weeks and persists for years, conferring long-term protection. In serological studies of patients, IgM titers correlate with acute resolution, and a four-fold rise in IgG between acute and convalescent samples confirms exposure, though with other alphaviruses can complicate interpretation. T-cell responses are critical for viral clearance but also drive ; CD8+ T cells target infected cells via perforin/granzyme-mediated and IFN-γ production, while CD4+ T cells support B-cell maturation and amplify proinflammatory cytokines like TNF-α and IL-6 during the acute , which peaks around days 2-5 post-infection and correlates with severe . In mouse models, depletion of CD4+ T cells reduces joint inflammation without impairing clearance, suggesting their dual role in both resolution and , whereas regulatory T cells (Tregs) mitigate excessive responses to prevent tissue damage. Human cohort data indicate mixed Th1/Th17 profiles in acute CHIKV, with elevated IL-17 linked to persistent symptoms. Chronic symptoms, particularly persisting beyond 3 months in 30-60% of cases, involve debates over viral persistence versus post-infectious ; persistent CHIKV has been detected in and tissues up to 18 months post- via RT-PCR, suggesting low-level replication in fibroblasts or sustains . However, viable is rarely isolated from chronic joints, and some studies attribute symptoms to residual triggering autoreactive T cells or autoantibodies mimicking , as infiltrates show dominance without consistent viral . Empirical evidence favors a hybrid model, where extracellular or defective particles in joints provoke sustained innate activation via TLRs, independent of productive , though high-inoculum models demonstrate dose-dependent persistence amplifying .

Clinical Presentation

Acute Phase Symptoms

Chikungunya virus infection typically manifests in the acute phase with an incubation period of 3 to 7 days following the bite of an infected Aedes mosquito. The illness begins abruptly with high fever, often exceeding 39°C and reaching up to 40°C, accompanied by severe polyarthralgia affecting small joints symmetrically, such as the hands, wrists, ankles, and feet. Myalgia, headache, and fatigue are also common, with the arthralgia described as debilitating and sometimes incapacitating patients. A appears in approximately 40-50% of cases, often starting on the trunk and spreading to the limbs, typically 2-5 days after fever onset. Additional symptoms may include , gastrointestinal disturbances such as and , and mild . Neurological involvement, including or , occurs rarely during this phase. The acute symptoms generally resolve within 7 to 10 days, though fever may biphasic in some instances. Asymptomatic infections account for 3% to 28% of cases, as determined by seroprevalence studies in outbreak settings. Symptomatic acute phase presentation shows high for fever (over 90%) and (nearly 100%) in confirmed cases.

Chronic and Long-Term Effects

Approximately 40-60% of chikungunya patients develop persistent joint pain lasting beyond three months post-infection, with cohort studies reporting prevalence rates of 52% at six months, declining to 27% at 12 months and 14% at 18 months in some populations. In other longitudinal assessments, up to 64% of cases exhibit chronic persisting for years, often in a relapsing-remitting affecting multiple joints symmetrically, particularly distal extremities. accompanies these symptoms in a majority of chronic cases, alongside myalgias and occasional cognitive impairments such as deficits, with non-rheumatic manifestations like asthenia reported in up to 50% of patients at five years follow-up. Risk factors for chronic sequelae include advanced age over 40 years, , and severe acute-phase , with females demonstrating higher incidence rates in multiple cohorts due to potential differences in immune responses or hormonal influences. Elderly patients face elevated risks of debilitating leading to functional limitations, while overall long-term affects about 40% beyond six months and 28% at 18 months. Pathogenic mechanisms remain debated, with evidence supporting low-level viral persistence or RNA retention in synovial tissues as drivers of ongoing , evidenced by detection of chikungunya antigens in joint biopsies years post-infection, rather than purely autoimmune processes. Alternative hypotheses invoke infection-triggered , including autoantibodies targeting joint tissues, though studies emphasize viral products sustaining immune activation over de novo . These effects impose substantial burdens, contributing to an estimated 1.95 million -adjusted life years (DALYs) globally from 18.7 million cases between 2011 and 2020, with chronic underestimated in routine due to focus on acute metrics. Rare fatalities occur from complications such as secondary infections or cardiovascular strain in severe chronic cases, though direct mortality remains low at under 0.01%.

Diagnosis

Laboratory Methods

Detection of chikungunya virus (CHIKV) RNA via real-time (RT-PCR) serves as the primary laboratory method for diagnosing acute infections, particularly in serum or plasma collected within the first 5–7 days after symptom onset, when is highest. This technique targets conserved regions of the viral genome, such as the nonstructural polyprotein or envelope genes, offering high , with limits of detection as low as 10–100 viral RNA copies per microliter in validated assays like the CDC's Trioplex RT-PCR. RT-PCR is preferred over other methods during this window due to its ability to confirm active replication before occurs. Serological testing, including IgM capture enzyme-linked immunosorbent assay (MAC-ELISA), becomes the mainstay for after the first week of illness, detecting anti-CHIKV IgM antibodies in serum that typically appear by days 5–7 and persist for weeks to months. IgM exhibits sensitivities of 80–95% in convalescent samples but requires confirmation to rule out with related alphaviruses, often via plaque reduction neutralization tests (PRNT) that quantify neutralizing antibodies by measuring 50–90% reduction in viral plaques on monolayers. PRNT, while gold-standard for serological specificity, demands biosafety level 3 facilities and live virus handling, limiting its routine use. Virus isolation in cell culture, such as on Vero or C6/36 cells, remains feasible during peak viremia but is infrequently performed due to time requirements (3–7 days), biohazard risks, and lower sensitivity compared to RT-PCR. In endemic regions, point-of-care (POC) diagnostics face significant barriers, including the scarcity of validated rapid tests—few CHIKV-specific antigen or antibody RDTs exist, with most relying on unvalidated or cross-reactive platforms—and infrastructure limitations like unreliable electricity and trained personnel, exacerbating delays in resource-poor settings where over 90% of cases occur. Efforts to develop affordable POC RT-PCR or lateral flow assays continue, but current options often cost $10–50 per test and require centralized labs, hindering timely outbreak response.

Differential Considerations

Chikungunya virus (CHIKV) infection presents with acute fever, , and severe that overlaps with several arboviral and non-arboviral conditions, necessitating careful clinical distinction to avoid misdiagnosis. Primary differentials include (DENV) infection, characterized by similar febrile illness and but differentiated by CHIKV's more intense symmetric and alongside relative absence of , which is common in dengue after day 3 of fever. (ZIKV) infection shares mild fever and but typically features less severe joint involvement and , with CHIKV exhibiting higher fever peaks and pronounced arthritic symptoms. Non-infectious mimics, particularly in the post-acute phase, include (RA), where CHIKV's sudden onset of symmetric small-joint involvement contrasts with RA's insidious progression, though chronic CHIKV may serologically resemble seronegative RA without meeting full diagnostic criteria. Other considerations encompass , , and , differentiated by epidemiological clues such as travel to endemic areas and mosquito exposure, which heighten suspicion for CHIKV over sporadic bacterial or protozoal illnesses. Co-infections with DENV or Oropouche virus (OROV) complicate differentiation, occurring in approximately 2.5% of cases globally for dengue-CHIKV and sporadically with OROV in overlapping transmission zones, amplifying symptom severity without unique syndromic features and underscoring the role of vector exposure history in syndromic assessment. Field studies report misdiagnosis rates of up to 9% overdiagnosis in elderly patients due to attribution and higher underdiagnosis in acute settings from symptom overlap, emphasizing syndromic integrating travel and vector context to mitigate errors.

Treatment and Management

Acute Supportive Care

Supportive care forms the cornerstone of management for the acute phase of chikungunya , which typically lasts 7–10 days and resolves spontaneously in the majority of cases without antiviral agents. Emphasis is placed on non-pharmacological measures, including ample to mitigate exacerbation of through physical activity and sufficient oral fluid intake to counteract fever-induced . These interventions address the self-limiting nature of the illness, where subsides within 5–10 days and acute symptoms abate without . For pharmacological symptom control, (acetaminophen) is the preferred agent for reducing fever and alleviating joint and muscle pain, with dosing aligned to standard guidelines. Nonsteroidal anti-inflammatory drugs (NSAIDs) may be considered after dengue co-infection is excluded, as their early use carries risks of or hemorrhage in overlapping arboviral epidemics; however, direct evidence of such risks in isolated chikungunya cases remains limited. Aspirin is contraindicated due to potential associations with hemorrhagic tendencies in febrile illnesses. Hospitalization criteria include signs of severe (e.g., , altered mental status), hemodynamic instability, or unresponsive to outpatient measures, with hospitalization rates ranging from 0.5% to 8.7% overall but higher among infants and elderly patients. Inpatient monitoring is warranted for rare acute complications such as , , or neurological manifestations, involving fluid resuscitation, electrolyte correction, and supportive organ function assessment as needed. Recovery timelines without intervention show most individuals regaining baseline function by 10–14 days post-onset, underscoring the efficacy of conservative management.

Interventions for Chronic Symptoms

Physiotherapy and targeted exercise programs form the cornerstone of interventions for chronic chikungunya-associated , focusing on restoring mobility, muscle strength, and functional capacity. Resistance training has been shown to significantly improve physical function in patients with persistent musculoskeletal symptoms beyond the acute phase, with randomized controlled trials demonstrating reductions in pain and enhancements in . Kinesiotherapy, involving structured movements, similarly increases muscle strength and flexibility when applied as a standalone intervention in post-chikungunya cohorts. Low-impact exercises, such as gentle and aerobic activities, are particularly beneficial for older patients or those with severe , promoting gradual recovery without exacerbating . In refractory cases resembling , disease-modifying antirheumatic drugs (DMARDs) like (MTX) have demonstrated efficacy in reducing joint inflammation and . Systematic reviews of clinical studies indicate that MTX alleviates chronic chikungunya arthritis symptoms, with improvements in disease activity scores and justification for its broader evaluation in this context. Biologic agents have been employed in a subset of patients unresponsive to MTX or with contraindications, comprising about 13% in one case series, though data remain limited to observational reports rather than large trials. Chronic symptoms often follow a relapsing-remitting pattern, with longitudinal studies reporting episodic in up to 60% of patients over three years post-infection. Spontaneous resolution occurs at an average rate of 10.85% per month across cohorts, corresponding to a median time to full resolution of approximately 6-7 months, though persistence beyond two years affects a minority with severe baseline . Adjunctive therapies, including herbal anti-inflammatories like , show preliminary inhibition of viral replication and inflammation but lack robust clinical evidence for alleviating chronic joint symptoms in human trials. Psychological support is recommended to address associated emotional distress and , as long-term chikungunya impairs daily functioning and , with qualitative studies highlighting needs for strategies amid and .

Pharmacological Options and Limitations

No specific antiviral drug has been approved for chikungunya virus (CHIKV) infection as of 2025, with treatment relying primarily on symptomatic relief through analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) such as paracetamol or ibuprofen to manage fever, arthralgia, and myalgia. Corticosteroids, like prednisone, may be employed short-term for severe, refractory joint inflammation in the subacute phase, typically at low doses (e.g., 5-10 mg daily) tapered over weeks, but guidelines caution against prolonged use due to risks of rebound arthritis, immunosuppression, and secondary infections in endemic tropical settings. NSAIDs carry limitations including gastrointestinal irritation, potential exacerbation of thrombocytopenia—a common CHIKV complication—and contraindications in patients with renal impairment or bleeding risks, necessitating careful monitoring in resource-limited areas where access to alternatives is restricted. Investigational antivirals, such as (T-705), have demonstrated and murine inhibition of CHIKV replication by targeting viral , reducing viral loads in acute phases but showing limited systemic efficacy in clinical contexts due to suboptimal and emergence of resistance mutations. Phase II trials and repurposing studies report modest viral clearance (e.g., EC50 values around 20-50 μM in cell lines), yet no significant reduction in chronic symptoms or approval has followed, hampered by side effects like , teratogenicity, and inconsistent dosing in outbreak scenarios. Other candidates, including direct-acting antivirals repurposed from hepatitis C (e.g., simeprevir), exhibit synergistic effects in preclinical models by disrupting multiple CHIKV lifecycle stages, but human trials remain absent, underscoring efficacy gaps and the need for larger randomized controlled studies. Off-label use of these agents persists in severe cases amid debates over risk-benefit ratios, particularly in low-resource tropics where economic barriers—such as high costs of investigational drugs (e.g., regimens exceeding $100 per course) and disruptions—limit equitable access, exacerbating disparities in outcomes for vulnerable populations. Overall, pharmacological options fail to address viral persistence or chronic in up to 30-50% of cases, highlighting the imperative for targeted therapies beyond palliation.

Prevention and Control

Vector Management

Vector management for Chikungunya focuses on controlling and mosquitoes through source reduction and chemical interventions. Source reduction entails eliminating larval breeding sites, such as discarding containers holding stagnant water and improving urban drainage to prevent accumulation. Community-led clean-up campaigns have demonstrated efficacy in reducing mosquito densities, with studies indicating that targeted removal of productive breeding habitats can lower vector populations and interrupt transmission cycles. Chemical controls complement these efforts, including application in identified breeding sites and ultra-low volume (ULV) spraying of adulticides like pyrethroids around outbreak foci, typically within a 250-meter radius of cases. Insecticide resistance poses a significant limitation to chemical strategies. Populations of A. aegypti and A. albopictus exhibit widespread resistance to pyrethroids such as and , as well as organophosphates like , driven by mechanisms including target-site mutations and enhanced metabolic detoxification. In regions with frequent outbreaks, such as South-East Asia, both species show resistance to and multiple classes of s, reducing the effectiveness of routine spraying campaigns. Perifocal , combining source reduction with insecticide application around confirmed cases, has shown potential to curtail outbreak spread in modeling studies, though real-world efficacy depends on rapid implementation and local vector susceptibility. Urban density and exacerbate control challenges by facilitating vector proliferation. High population concentrations in cities create abundant artificial breeding sites, complicating comprehensive source reduction despite community efforts. Warmer temperatures and altered precipitation patterns extend mosquito activity seasons and expand ranges, increasing transmission risks in previously unaffected areas. Sustained, integrated programs prioritizing proactive larval control yield better long-term outcomes than reactive adulticiding, which addresses symptoms of infestation rather than root causes, though resource constraints often favor episodic responses during outbreaks.

Vaccination Developments

The first licensed chikungunya vaccine, Ixchiq (VLA1553), a live-attenuated single-dose formulation developed by Valneva, received FDA approval on November 9, 2023, for individuals aged 18 years and older at high risk of exposure, such as travelers to endemic areas. Clinical trials demonstrated with neutralizing antibody seroprotection rates of 98.4% at day 28 post- and 96.2% at month 6, serving as a surrogate for protection against ; however, direct against symptomatic disease, including , has been estimated around 65-83% based on challenge models and post-exposure correlates, though no large-scale field efficacy trials exist due to the sporadic nature of outbreaks. Common adverse events included chikungunya-like symptoms such as fever, joint pain, fatigue, headache, and injection-site tenderness, affecting up to 63% of recipients through 180 days, with less than 2% experiencing severe reactions requiring intervention; serious events were rare but prompted warnings for potential prolonged mimicking natural infection. Post-approval safety monitoring revealed elevated risks, leading to FDA and CDC recommendations on May 9, 2025, to pause use in adults aged 60 and older due to reports of severe chikungunya-like illnesses, including cardiac and neurological events and fatalities in seniors. This culminated in a full U.S. license suspension on August 22, 2025, amid ongoing identifying 28 adverse events in 2024, including six serious neurological or cardiac cases. Contraindications include immunocompromised states, , , and history of severe to components, limiting broad deployment; precautions extend to older adults and those with comorbidities, where risks may outweigh benefits absent imminent exposure. Single-dose administration avoids booster logistics but raises questions on long-term durability, with antibody persistence data supporting at least 6-12 months of protection, though real-world waning in endemic settings remains untested. Ongoing developments focus on alternative platforms to address live-virus limitations. Bavarian Nordic initiated a Phase 3 trial of its virus-like particle (VLP) vaccine, CHIKV VLP (PXVX0317), in pediatric populations aged 12-17 on June 12, 2025, aiming to expand from adult approvals and overcome contraindications via non-replicating design; earlier trials showed 63% adverse event rates but strong immunogenicity without live-virus risks. Valneva reported positive Phase 2 results for Ixchiq in children on June 5, 2025, with sustained antibodies, though not yet licensed for this group. Inactivated and subunit candidates, supported by organizations like CEPI, are in late-stage trials targeting endemic access, but challenges persist: high costs favor traveler markets over low-income regions, sporadic epidemiology hinders efficacy demonstration, and prior infections may reduce vaccine uptake or mask benefits, complicating herd immunity thresholds estimated at 60-80% in models yet unachievable without mass campaigns. Equity gaps exacerbate rollout limitations, as vaccines like Ixchiq prioritize short-term protection for non-immune visitors rather than sustained community immunity in transmission hotspots.

Individual and Community Measures

Individuals can reduce the risk of chikungunya infection by applying repellents containing 20-30% to exposed skin, which provides up to 5-10 hours of protection against bites depending on concentration and environmental factors. Wearing long-sleeved shirts, long pants, and socks, especially when treated with , further diminishes bite exposure, with studies demonstrating protective efficacies exceeding 90% in controlled settings when combined with skin repellents. Additional behaviors include installing fine-mesh screens on windows and doors, using air conditioning or bed nets indoors, and limiting outdoor activities during peak mosquito biting times at dawn and dusk, collectively contributing to 70-90% reductions in bite incidence based on field evaluations of integrated personal protections. Community-level actions emphasize local surveillance and rapid reporting of suspected cases to facilitate early intervention, as empirical reviews indicate that grassroots detection outperforms delayed institutional responses in containing localized transmission. Public education campaigns promoting consistent use of personal protective measures have shown variable adoption rates—such as 18% for repellents in some outbreak settings—but correlate with lowered incidence where behavioral compliance is high, underscoring the causal role of individual accountability over reliance on centralized aid. Travelers face elevated risks in outbreak zones, prompting agencies like the CDC to issue Level 2 advisories for areas including Guangdong Province, , where over 10,000 cases were reported by August 2025, and the , with 212,029 suspected infections across 14 countries as of August 2025. Risk stratification advises enhanced precautions for visits to these endemic or regions, prioritizing self-reliant avoidance strategies given the virus's vector dependence and potential for imported cases to seed local outbreaks.

Prognosis

Mortality and Recovery Rates

The for chikungunya is typically low, estimated at less than 1% of symptomatic cases overall, with approximately one death per 1,000 infections primarily occurring among neonates, infants, the elderly, and individuals with underlying comorbidities such as or . In hospitalized or severe cases, rates can rise substantially; for instance, admissions have shown fatality rates up to 21%, though these represent a small fraction of total infections. Mortality is driven by complications like multi-organ failure or exacerbated pre-existing conditions rather than direct viral effects in most instances. Recovery from the acute phase occurs in the majority of patients within 1–3 weeks, with full resolution of fever and most symptoms in over 90% of uncomplicated cases, though severe joint pain may linger longer initially. However, chronic post-chikungunya musculoskeletal disorders affect 30–50% of cases, manifesting as persistent , , or lasting beyond 3 months and up to years, with prevalence rates of 40% at 6 months and 28% at 18 months in longitudinal cohorts. These impairments often lead to reduced and productivity losses equivalent to years of disability-adjusted life years per infection in affected populations. Factors influencing recovery include age, with adults over 40 years facing higher risks of chronicity compared to children, who generally exhibit faster resolution but may still report post-acute in 23–36% of cases. sex, comorbidities like or , and severe initial pain intensity correlate with prolonged symptoms, while genetic variations in genes, such as those affecting neutralizing production, are under investigation as potential modifiers. Longitudinal studies underscore that while acute mortality is negligible, the underrecognized burden of chronic necessitates emphasis beyond fatality metrics alone.

Factors Influencing Outcomes

Pre-existing comorbidities significantly influence the severity and persistence of chikungunya symptoms. , in particular, is associated with more severe acute manifestations, prolonged , and higher hospitalization rates compared to non-diabetic patients. Other conditions such as (prevalent in approximately 30% of cases), (15%), , and independently correlate with increased risk of chronic joint pain lasting beyond three months. from uncontrolled further exacerbates joint inflammation and tissue degeneration during infection, likely through impaired antiviral immunity and heightened inflammatory responses. Host genetic variations also modulate outcomes, with specific human leukocyte antigen (HLA) alleles linked to chronicity. Among patients developing persistent symptoms on Reunion Island, HLA-DRB101 and HLA-DRB104 were overrepresented, suggesting these alleles impair effective viral clearance or amplify autoimmune-like responses in joints. The HLA-DRB104-DQB103 confers heightened susceptibility to , potentially by altering T-cell mediated control, while certain protective alleles like HLA-DRB1*11 may mitigate progression to severe disease. These associations underscore the role of innate immune genetics in determining whether acute resolves or evolves into debilitating long-term . Viral strain differences contribute to variable , independent of host factors. Strains from distinct lineages, such as the Asian lineage SL15649, demonstrate higher neuroinvasion and disease severity in murine models compared to East/Central/South African or lineages, correlating with elevated viral titers in neural tissues. Minor intraclade variations further influence replication efficiency and host cell interactions, though these effects are often subtle and compounded by passage history in lab settings. In resource-limited endemic areas, suboptimal nutritional status impairs immune competence, leading to dysregulated responses that worsen chikungunya , as observed in broader infections where malnourishment heightens viral persistence and tissue damage. Limited access to timely supportive care, prevalent in low-income settings, exacerbates severity by delaying hydration, , and monitoring for complications, thereby increasing the transition to chronic phases.

Epidemiology

Global Patterns and Risk Factors

Chikungunya virus is endemic in tropical and subtropical regions across , Southeast and , and the , where Aedes aegypti and Aedes albopictus mosquitoes facilitate sustained transmission. As of July 2025, transmission has been documented in 119 countries and territories worldwide, reflecting the virus's broad geographical footprint driven by vector distribution rather than isolated climatic shifts. Seroprevalence studies indicate high exposure in endemic areas, with rates exceeding 50% in certain island populations, such as 63% antibody detection in sera from affected communities, underscoring the virus's entrenchment in these locales. Vector range expansion, propelled by global trade and human-mediated introductions rather than primary environmental reconfiguration, has amplified the virus's reach into previously unaffected temperate zones. exacerbates transmission by concentrating human hosts and creating abundant breeding sites for species in densely populated settings with inadequate infrastructure. International travel serves as a key disseminator, seeding local outbreaks from imported cases in high-density hubs. Co-circulation with heightens risks due to shared vectors and overlapping clinical presentations, which can complicate and strain systems. Population density and suboptimal further amplify vulnerability by fostering proliferation in peri-urban areas. However, official data likely underestimates true incidence, as passive reporting systems overlook infections—estimated to comprise a significant proportion of cases—and exhibit biases from inconsistent testing and healthcare access disparities. This underreporting obscures the full epidemiological burden, particularly in resource-limited settings. One of the largest recorded outbreaks began in 2004 on islands in the , including , where approximately 266,000 cases—about one-third of the population—were reported by mid-2005, with the virus adapting via an E1-A226V mutation that enhanced transmission by mosquitoes, enabling urban spread. The epidemic extended to in 2005–2006, resulting in over 1.3 million suspected cases across multiple states, marking a re-emergence after decades of sporadic activity. This event highlighted travel-linked dissemination, as infected individuals carried the virus to new regions. In 2013, chikungunya was introduced to the via travelers from and , sparking rapid autochthonous transmission starting in Saint Martin and spreading to over 45 countries and territories. By 2015, the estimated more than 1.7 million suspected cases across the region, with peak annual figures exceeding 1 million in 2014–2016, driven by the same Aedes vectors prevalent in urban environments. This introduction underscored vulnerabilities in non-endemic areas with suitable mosquito populations and human mobility. The 2020s have seen a surge in global incidence, with ongoing outbreaks in , , and the fueled by urban strains and international travel. In 2025, the reported 445,271 suspected and confirmed cases and 155 deaths across 40 countries from January 1 to September 30, reflecting intensified transmission. Notable activity included over 6,000 cases in China's Guangdong Province by August, the largest outbreak there since 2010; more than 212,000 suspected cases and 110 deaths in 14 American countries by early August; and elevated reports from , , and African nations. These trends indicate persistent evolutionary pressures favoring vector competence and human-vector contact in densely populated areas.

Historical Context

Discovery and Early Spread

The chikungunya virus (CHIKV) was first isolated during an outbreak of febrile illness in the Newala district of southern Tanganyika Territory (present-day Tanzania) in July 1952. The outbreak affected a Makonde-speaking village, where patients exhibited severe arthralgia causing a characteristic stooped posture, from which the disease derived its name ("chikungunya" meaning "to become contorted" in the Makonde language). The virus was recovered in early 1953 from the serum of febrile patients and from field-collected Aedes aegypti mosquitoes via inoculation into newborn mice, distinguishing it from dengue despite symptomatic similarities. Following its identification, CHIKV circulated endemically in , with documented outbreaks in (1963) and (1966), primarily vectored by A. aegypti in urban and peri-urban settings. By the mid-1960s, the virus spread to , causing epidemics in (1963–1964) and (1967–1968), marking the beginning of its sylvatic-to-urban transmission cycles involving human-mosquito-human amplification. Early revealed high attack rates, often exceeding 50% in affected communities, with symptoms including sudden fever, , and debilitating joint pain, though serological cross-reactivity with other alphaviruses complicated initial diagnoses. Through the 1970s and into the 1980s, CHIKV outbreaks continued sporadically in East and and , but activity waned globally by the late 1980s, entering a period of relative quiescence attributed to factors such as , efforts, and possible viral attenuation. Confirmation of CHIKV in these early events relied on virus isolation and hemagglutination inhibition assays for serological detection, which helped differentiate it from dengue after initial misattributions. This lull persisted until post-2000 adaptations, including a key alanine-to-valine substitution at position 226 in the E1 glycoprotein, enhanced CHIKV's transmissibility by , facilitating renewed spread beyond traditional A. aegypti ranges.

Pandemics and Evolutionary Changes

The 2005–2006 outbreak on Réunion Island marked a turning point in chikungunya (CHIKV) , with approximately 266,000 cases reported among a population of 800,000, driven by the emergence of the East/Central/South African (ECSA) genotype's lineage (IOL). This event was causally linked to a key adaptive in the E1 (A226V), which enhanced viral replication and dissemination in mosquitoes, a species more tolerant of temperate climates and urban environments than the primary vector . The 's selective advantage arose from improved viral fitness in A. albopictus salivary glands and midguts, facilitating efficient urban transmission cycles where human-mosquito contact is intensified by and standing water in man-made containers. Phylogenetic analyses confirm the IOL's rapid diversification post-Réunion, with substitution rates estimated at 8.46 × 10⁻⁴ per per year, underscoring its evolutionary acceleration amid high and vector competence. This viral adaptation intersected with anthropogenic factors, enabling CHIKV's escape from sylvatic reservoirs into sustained peri-urban and urban epidemics. The E1-A226V variant's compatibility with A. albopictus—whose global range has expanded via tire trade and lacks A. aegypti's strict tropical constraints—propagated the IOL across the islands, , and , supplanting less transmissible lineages through competitive exclusion evidenced in genomic sequencing of outbreak strains. Human mobility, particularly , acted as a seeding mechanism; for instance, a single viraemic traveler from , , introduced the IOL to in 2007, igniting the first documented autochthonous European outbreak with over 200 cases in , amplified by local A. albopictus populations. Such introductions exploit the virus's short extrinsic (2–3 days in competent vectors) and prolonged (up to 10 days), outpacing containment in non-endemic settings with established vectors. Evolutionary pressures from these expansions have favored IOL dominance, as Bayesian phylogeographic reconstructions trace its dissemination from East Africa through Kenya and Indian Ocean foci, with mutations like E1-K211E/E2-V264A further boosting infectivity in secondary vectors and hosts. Unlike enzootic cycles reliant on forest primates, the adapted strains thrive in anthropogenically modified landscapes, where vector proliferation in urban detritus decouples transmission from wildlife reservoirs, perpetuating human-centric epidemics. This shift, while not conferring cholesterol dependence or altered fusion pH thresholds, correlates with heightened epidemic potential, as modeled by increased vector densities and survival in urban heat islands.

Research Frontiers

Vaccine and Antiviral Advances

The live-attenuated VLA1553 (IXCHIQ), developed by Valneva, received marketing authorization from the in April 2024 and demonstrated in phase 3 trials that 98% of vaccinated participants achieved neutralizing titers (NT80) of at least 100 by day 28 post-vaccination, with seroprotection rates exceeding 97% persisting up to two years. initiated a phase 3 study of its CHIKV candidate in June 2025, building on earlier data showing neutralizing induction in over 80% of recipients within 21 days, aimed at supporting regulatory approval for broader populations including older adults. Similarly, the (VLP) PXVX0317 advanced through phase 3 evaluation, eliciting approximately 95% short-term seroresponse rates across genotypes in robust trials. Antiviral development has focused on inhibitors targeting the viral (RdRp, or nsP4), a key replication absent in host cells, with structure-based screening identifying small-molecule candidates that reduce Chikungunya virus replication by disrupting activity. A September 2025 high-throughput screen yielded novel RdRp inhibitors with micromolar potency against Chikungunya, though efficacy in animal models remains preclinical, highlighting gaps in translating activity to clinical protection during acute infection. No antivirals have reached phase 3 trials, and current candidates show limited impact on chronic joint symptoms post-acute phase. Key challenges include assessing long-term immunity duration beyond two years, where antibody waning could necessitate boosters, and ensuring cross-lineage against evolving strains, as while VLA1553 induces antibodies neutralizing multiple genotypes, heterologous challenge models reveal variable against distantly related alphaviruses like Mayaro virus. Live-attenuated vaccines like VLA1553 also face safety concerns in immunocompromised individuals, evidenced by rare adverse events such as febrile encephalopathy in elderly recipients. Following expanded outbreaks in 2025 affecting regions like the islands and extending to 119 countries, funding has shifted toward private-sector partnerships, with the (CEPI) allocating up to $41.3 million to Valneva in 2024 for equitable access manufacturing, complemented by collaborations with for Asian production scaling. These efforts prioritize phase 3 pediatric trials and low-income over prior public-sector dominance, driven by commercial incentives from endemic demand.

Debates on Chronicity and Burden

The extent to which chikungunya virus infection leads to chronic symptoms remains a point of contention, with public health organizations like the emphasizing the acute phase while acknowledging potential for prolonged joint pain without quantifying its prevalence. Empirical studies, however, report higher rates of chronic and , ranging from 34% to 51% of symptomatic cases persisting beyond six months or resulting in long-term impairment.00810-1/fulltext) In specific cohorts, such as those followed post-outbreak, up to 94% of patients classified with chronic disease exhibited persistent joint pain, contrasting with estimates of chronicity below 40% in broader reviews that may underrepresent severe cases due to loss to follow-up or diagnostic variability. The immunopathogenesis underlying this chronicity—potentially involving persistent viral antigens, autoimmune responses, or inflammatory cascades—remains unresolved, complicating attribution and underlining gaps in causal understanding beyond acute . Assessments of further highlight discrepancies, as disability-adjusted life years (DALYs) from chikungunya are often underestimated by focusing on mortality and acute morbidity rather than chronic . Global estimates indicate 1.95 million DALYs lost between 2011 and 2020, averaging 195,000 annually, predominantly from years lived with due to and . Economic analyses reveal losses as the dominant cost driver, exceeding direct treatment expenses; for instance, during India's 2006 , deficits totaled at least $8.5 million, while in Colombia's 2014–2015 outbreak, average per-case losses reached $81.3, amplifying societal impacts through workforce absenteeism and reduced output. These , often sidelined in acute-centric modeling, suggest the true economic toll—potentially billions in high-burden regions—warrants reevaluation to capture long-term sequelae like chronic . Policy responses have prioritized and acute , potentially overlooking chronic burdens that drive sustained healthcare demands and . This overfocus risks underfunding longitudinal studies and rehabilitation, as evidenced by calls for enhanced post-infection tracking to quantify and inform beyond outbreak containment. In regions with recurrent transmission, such as the and islands, failure to integrate chronic metrics into burden estimates may perpetuate incomplete assessments, despite that up to half of infections yield measurable long-term functional impairment.00810-1/fulltext)

References

  1. https://www.who.int/news-room/fact-sheets/detail/chikungunya
  2. https://www.cdc.gov/chikungunya/php/transmission/index.html
  3. https://www.cdc.gov/chikungunya/causes-and-spread/index.html
  4. https://stacks.cdc.gov/view/cdc/21259/cdc_21259_DS1.pdf
  5. https://www.cdc.gov/chikungunya/symptoms-diagnosis-treatment/index.html
  6. https://www.cdc.gov/chikungunya/hcp/clinical-signs/index.html
  7. https://www.who.int/health-topics/chikungunya
  8. https://cdn.who.int/media/docs/default-source/documents/epp/ezh/chikungunya-epidemiology-update_11june2025.pdf
  9. https://www.cdc.gov/chikungunya/prevention/index.html
  10. https://cdn.who.int/media/docs/default-source/immunization/pdvac/pdvac-2023/09_chikungunya_vaccine_sessions_121223-merged.pdf?sfvrsn=ee311945_1
  11. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.689979/full
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC10564160/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC10058558/
  14. https://wwwnc.cdc.gov/eid/article/21/2/14-1121_article.htm
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6816471/
  16. https://www.sciencedirect.com/science/article/pii/S1665579615000587
  17. https://www.sciencedirect.com/science/article/pii/S1201971221007645
  18. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006835
  19. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-10102-y
  20. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0012349
  21. https://journals.asm.org/doi/10.1128/mbio.02449-17
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC9147731/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC12398651/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC11126297/
  25. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.744164/full
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC6410217/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC7092809/
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC12449805/
  29. https://www.sciencedirect.com/science/article/pii/S0092867419303927
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC4517121/
  31. https://www.nature.com/articles/s41467-022-32431-9
  32. https://portlandpress.com/bioscirep/article/39/6/BSR20191077/219336/Conformational-changes-in-Chikungunya-virus-E2
  33. https://journals.asm.org/doi/10.1128/JVI.01732-21
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC5330729/
  35. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007703
  36. https://www.mdpi.com/1999-4915/17/4/509
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC9930444/
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC11334481/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC7278350/
  40. https://journals.asm.org/doi/10.1128/jvi.00775-24
  41. https://journals.asm.org/doi/10.1128/jvi.00767-10
  42. https://pubmed.ncbi.nlm.nih.gov/33323678/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC2950581/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC5300252/
  45. https://www.jci.org/articles/view/84417
  46. https://virologyj.biomedcentral.com/articles/10.1186/s12985-025-02721-x
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC8878350/
  48. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0299521
  49. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.00287/full
  50. https://www.tandfonline.com/doi/full/10.1080/22221751.2024.2304061
  51. https://www.mdpi.com/1999-4915/16/9/1387
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3838294/
  53. https://medicine.washu.edu/news/arthritis-causing-virus-hides-in-body-for-months-after-infection/
  54. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010149
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC8127625/
  56. https://journals.asm.org/doi/10.1128/spectrum.02656-24
  57. https://academic.oup.com/qjmed/article/117/7/489/7611656
  58. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1007993
  59. https://academic.oup.com/cid/article/49/6/942/335046
  60. https://emedicine.medscape.com/article/2225687-clinical
  61. https://www.ncbi.nlm.nih.gov/books/NBK534224/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC11796447/
  63. https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/chikungunya.html
  64. https://academic.oup.com/jid/article/214/suppl_5/S441/2632641
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC8627389/
  66. https://academic.oup.com/cid/article/47/4/469/302619
  67. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07922-1
  68. https://www.sciencedirect.com/science/article/abs/pii/S1386653223002330
  69. https://www.sciencedirect.com/science/article/abs/pii/S1477893920300867
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC4842256/
  71. https://pubmed.ncbi.nlm.nih.gov/28376065/
  72. https://www.sciencedirect.com/science/article/pii/S1477893922002800
  73. https://pubmed.ncbi.nlm.nih.gov/39627007/
  74. https://gh.bmj.com/content/9/12/e016648
  75. https://stacks.cdc.gov/view/cdc/49354/
  76. https://wwwnc.cdc.gov/eid/article/22/10/15-1784_article.htm
  77. https://www.fda.gov/media/123606/download
  78. https://emedicine.medscape.com/article/2225687-workup
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC12203700/
  80. https://stacks.cdc.gov/view/cdc/49354/cdc_49354_DS1.pdf
  81. https://pmc.ncbi.nlm.nih.gov/articles/PMC5638038/
  82. https://experiments.springernature.com/articles/10.1007/978-1-4939-3618-2_25
  83. https://pubmed.ncbi.nlm.nih.gov/27233280/
  84. https://www3.paho.org/hq/dmdocuments/2010/p4.lanciottiCHIK%2520PAHO%2520mtg%2520Peru%25202010_1_1.pdf
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC10383795/
  86. https://www.medrxiv.org/content/10.1101/2022.01.28.22270018v1.full-text
  87. https://www.tandfonline.com/doi/full/10.1586/eri.11.132
  88. https://journals.lww.com/pidj/fulltext/2012/05000/differential_diagnosis_of_chikungunya%2C_dengue.8.aspx
  89. https://www.sciencedirect.com/science/article/pii/S0185106316301135
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC6771335/
  91. https://www.sciencedirect.com/science/article/abs/pii/S0001706X22001061
  92. https://pubmed.ncbi.nlm.nih.gov/32041646/
  93. https://pubmed.ncbi.nlm.nih.gov/30080240/
  94. https://agsjournals.onlinelibrary.wiley.com/doi/pdf/10.1111/jgs.15492
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC5530543/
  96. https://www.cdc.gov/chikungunya/hcp/treatment-prevention/index.html
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC6347300/
  98. https://pubmed.ncbi.nlm.nih.gov/33448754/
  99. https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-023-06450-6
  100. https://medicopublication.com/index.php/ijpot/article/download/22193/17983/50106
  101. https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.23519
  102. https://pubmed.ncbi.nlm.nih.gov/29361202/
  103. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002137
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC8641736/
  105. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0011793
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC11654465/
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC9526181/
  108. https://emedicine.medscape.com/article/2225687-treatment
  109. https://www.sciencedirect.com/science/article/pii/S2255502117300445
  110. https://pmc.ncbi.nlm.nih.gov/articles/PMC8145424/
  111. https://www.sciencedirect.com/science/article/abs/pii/S0166354217304825
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC7239338/
  113. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2020.618624/full
  114. https://www.sciencedirect.com/science/article/pii/S0010482525003403
  115. https://pubmed.ncbi.nlm.nih.gov/40056839/
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC7769948/
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC7241847/
  118. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010199
  119. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0010244
  120. https://www.who.int/publications/i/item/sea-cd-334
  121. https://pubmed.ncbi.nlm.nih.gov/37609563/
  122. https://www.nature.com/articles/srep23997
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC5757676/
  124. https://www.nature.com/articles/s41598-017-03566-3
  125. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005176
  126. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-prevent-disease-caused-chikungunya-virus
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC10793683/
  128. https://www.chop.edu/vaccine-education-center/vaccine-details/chikungunya-disease-vaccines
  129. https://www.drugs.com/ixchiq.html
  130. https://www.cdc.gov/chikungunya/hcp/vaccines/index.html
  131. https://www.pharmacytimes.com/view/ixchiq-vaccine-linked-to-fatal-adverse-events-in-seniors-the-fda-and-cdc-urge-caution
  132. https://www.cdc.gov/chikungunya/vaccines/index.html
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC12355908/
  134. https://valneva.com/press-release/valneva-reports-positive-six-month-antibody-persistence-and-safety-phase-2-results-in-children-for-its-single-shot-chikungunya-vaccine-ixchiq/
  135. https://www.bavarian-nordic.com/investor/news/news.aspx?news=7238
  136. https://pmc.ncbi.nlm.nih.gov/articles/PMC11530495/
  137. https://cepi.net/chikungunya
  138. https://www.sciencedirect.com/science/article/pii/S0264410X24011654
  139. https://media.tghn.org/medialibrary/2025/04/Day_1_19Mar2025_ChikV_Phase_IV_Studies_agenda_and_slides.pdf
  140. https://www.nature.com/articles/s41541-025-01194-x
  141. https://www.nejm.org/doi/full/10.1056/NEJMoa011699
  142. https://www.sciencedirect.com/science/article/abs/pii/S1477893913001737
  143. https://parasitesandvectors.biomedcentral.com/articles/10.1186/s13071-018-3239-0
  144. https://pmc.ncbi.nlm.nih.gov/articles/PMC4871372/
  145. https://www.cdc.gov/mosquitoes/prevention/index.html
  146. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0212054
  147. https://pmc.ncbi.nlm.nih.gov/articles/PMC6392276/
  148. https://wwwnc.cdc.gov/travel/notices/level2/chikungunya-china
  149. https://www.sciencedirect.com/science/article/pii/S120197122500311X
  150. https://www.paho.org/en/news/29-8-2025-amid-localized-chikungunya-outbreaks-and-ongoing-oropouche-cases-paho-urges
  151. https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581
  152. https://www.cdc.gov/chikungunya/data-maps/index.html
  153. https://www.nature.com/articles/s41591-025-03703-w
  154. https://wwwnc.cdc.gov/eid/article/31/9/25-0554_article
  155. https://pmc.ncbi.nlm.nih.gov/articles/PMC11018361/
  156. https://www.ecdc.europa.eu/en/chikungunya/facts/factsheet
  157. https://pmc.ncbi.nlm.nih.gov/articles/PMC10197786/
  158. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0013580
  159. https://www.sciencedirect.com/science/article/pii/S1477893925000316
  160. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0011948
  161. https://pmc.ncbi.nlm.nih.gov/articles/PMC5899414/
  162. https://www.sciencedirect.com/science/article/pii/S1201971217303302
  163. https://academic.oup.com/ofid/article/5/1/ofx234/4788106
  164. https://pmc.ncbi.nlm.nih.gov/articles/PMC8888679/
  165. https://www.tandfonline.com/doi/full/10.1080/21505594.2024.2396484
  166. https://www.mdpi.com/1999-4915/15/5/1057
  167. https://pmc.ncbi.nlm.nih.gov/articles/PMC5844994/
  168. https://pmc.ncbi.nlm.nih.gov/articles/PMC6872174/
  169. https://www.frontiersin.org/journals/tropical-diseases/articles/10.3389/fitd.2024.1466207/full
  170. https://www.sciencedirect.com/science/article/pii/S1477893925000985
  171. https://idpjournal.biomedcentral.com/articles/10.1186/s40249-025-01364-y
  172. https://www.ajtmh.org/abstract/journals/tpmd/76/6/article-p1189.xml
  173. https://pmc.ncbi.nlm.nih.gov/articles/PMC6438455/
  174. https://www.mdpi.com/2071-1050/17/9/4077
  175. https://pmc.ncbi.nlm.nih.gov/articles/PMC12425392/
  176. https://www.nature.com/articles/s41467-025-58609-5
  177. https://pubmed.ncbi.nlm.nih.gov/29373771/
  178. https://academic.oup.com/jid/article/214/suppl_5/S436/2632642
  179. https://pmc.ncbi.nlm.nih.gov/articles/PMC4712202/
  180. https://www.sciencedirect.com/science/article/pii/S2667193X23002478
  181. https://www.ecdc.europa.eu/en/chikungunya-monthly
  182. https://beaconbio.org/en/report/?reportid=9c713bf1-3aa9-434f-a6bf-c86dbc29a172&eventid=f1e1f871-0572-4dd8-9fba-750825a935ad
  183. https://pmc.ncbi.nlm.nih.gov/articles/PMC12500152/
  184. https://wwwnc.cdc.gov/eid/article/21/4/14-1723_article
  185. https://pmc.ncbi.nlm.nih.gov/articles/PMC7114207/
  186. https://www.ijidonline.com/article/s1201-9712%2817%2930089-9/fulltext
  187. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002412
  188. https://pmc.ncbi.nlm.nih.gov/articles/PMC2134949/
  189. https://wwwnc.cdc.gov/eid/article/17/2/10-1056_article
  190. https://www.tandfonline.com/doi/full/10.1080/21505594.2024.2401985
  191. https://journals.asm.org/doi/10.1128/jvi.01603-09
  192. https://www.mdpi.com/1999-4915/17/3/430
  193. https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003301
  194. https://www.ecdc.europa.eu/en/chikungunya/threats-and-outbreaks/chikungunya-fever-eueea
  195. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018860
  196. https://www.ecdc.europa.eu/en/disease-vectors/facts/mosquito-factsheets/aedes-albopictus
  197. https://pmc.ncbi.nlm.nih.gov/articles/PMC8878743/
  198. https://www.biorxiv.org/content/10.1101/2024.03.15.585156v1.full-text
  199. https://academic.oup.com/jid/article/214/suppl_5/S453/2632632
  200. https://pmc.ncbi.nlm.nih.gov/articles/PMC3162544/
  201. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2824%2900357-8/fulltext
  202. https://www.clinicaltrials.gov/study/NCT05072080
  203. https://www.vax-before-travel.com/vaccines/vimkunya-chikungunya-vaccine
  204. https://www.nature.com/articles/s41598-022-14790-x
  205. https://www.sciencedirect.com/science/article/pii/S266702242300289X
  206. https://www.biorxiv.org/content/10.1101/2025.09.16.676555v1
  207. https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2469653
  208. https://www.mdpi.com/2076-393X/12/9/970
  209. https://academic.oup.com/ofid/article/12/9/ofaf550/8247336
  210. https://cepi.net/cepi-expands-partnership-valneva-413-million-support-broader-access-worlds-first-chikungunya
  211. https://european-biotechnology.com/sponsored-publications/2025-chikungunya-outbreak-a-global-health-challenge/
  212. https://valneva.com/press-release/valneva-successfully-expands-access-to-asia-for-its-chikungunya-vaccine-with-serum-institute-of-india/
  213. https://valneva.com/press-release/valneva-receives-first-marketing-authorization-for-ixchiq-in-a-chikungunya-endemic-country/
  214. https://www.sciencedirect.com/science/article/pii/S1684118225001409
  215. https://pmc.ncbi.nlm.nih.gov/articles/PMC12401649/
  216. https://www.mdpi.com/2414-6366/8/6/301
  217. https://pmc.ncbi.nlm.nih.gov/articles/PMC12074603/
  218. https://www.ispor.org/docs/default-source/euro2022/20221019---ispor-eu-poster-econ-boi-chik-pdf.pdf?sfvrsn=b6d1e32_0
  219. https://pmc.ncbi.nlm.nih.gov/articles/PMC10699624/
Add your contribution
Related Hubs
User Avatar
No comments yet.